Editorial

• Volume 13 Number 1/2 January/February 2012

Special reports

• Supplement: HIV testing and risks of sexual transmission

Conference reports

• 2nd International Workshop on HIV & Women, 9-10 January 2012, Bethesda, USA

• Similar efficacy and a few gender related differences in side effects with rilpivirine vs efavirenz at 96-weeks

• The effect of BMI on efficacy, safety and tolerability of lopinavir/r in women

• Hormonal contraception and higher risk of non-AIDS-defining events in Nashville cohort

• Poorer adherence and loss to follow up in Kenyan women who are pregnant when enrolled to ART programmes

• 5th HIV Persistence Workshop on HIV Reservoirs, 6-9 December 2011, West Indies

• Workshop report and commentary

Antiretrovirals

• Nevirapine prolonged release (PR) once-daily formulation available in the UK

• Etravirine 200 mg formulation available in UK

• Tenofovir label extended to paediatric indication

• FDA approve US paediatric dose for raltegravir

• FDA approve paediatric dose for darunavir

• Efavirenz dose increase to 800 mg QD with rifampin in patients >50 kg

Guidelines

• Draft BHIVA ARV treatment guidelines online for comment until 5 March

• BHIVA guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011

• Draft BHIVA pregnancy guidelines online for comment until 5 March

Paediatric care

• Delaying ART in childhood can reduce long-term CD4 count in adulthood

TB coinfection

• Need for expanded access to two promising MDR TB drugs

PK and drug interactions

• Interactions between nevirapine and antimalarials (artemether and lumefantrine)

• Interactions between antiretrovirals and complementary and African traditional medicines

• Drug interactions between sirolimus (rapamycin) and ARVs

• Contraceptive failure with etonogestrel implants and efavirenz: case reports

Opportunistic infections and complications

• No increased risk of non-AIDS deaths from cumulative use of ART in EuroSIDA cohort

Treatment access

• FDA approval of generic ARVs

• Disastrous warning for global HIV programmes in 2012

• Janssen block Patent Pool access to darunavir, rilpivirine and etravrine

• UNITAID continues funding the Patent Pool, paediatric HIV medicines and malaria

• Michel Kazatchkine resigns from Global Fund: Gabriel Jaramillo, Brazilian banker, to serve as general manager

• Call to Action on Global Fund restriction to new funding to 2014

• Analysis of why the Global Fund cancelled Round 11

• Reaction to the Global Fund’s decisions on Round 11 and grant renewals

• Activists oppose Gates Foundation funding study using low dose d4T

Transmission and prevention

• NICE guidance on increasing the uptake of HIV testing

Other news

• London Commissioning: new announcements

Book and film reviews

• Testosterone: A man’s guide: practical tips for boosting physical, mental and sexual vitality; by Nelson Vergel

On the web

• 2011 HIV Persistence Workshop

• A Call for Comprehensive Responses to HIV in People Who Use Drugs

• Achieving a cure for HIV infection: do we have reasons to be optimistic?

Future meetings

• 2012 conference listing

PDFs

• Volume 13 Number 1/2 January/February 2012 PDF